ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to […]

read more

Sorafenib versus observation following surgery for metastatic kidney cancer

A potential treatment for a selected group of patients with metastatic renal cell carcinoma (RCC) is nephrectomy followed by surgery to remove metastases (radical metastasectomy). After surgery, patients are usually followed by observation or treated with anti-cancer drugs. The RESORT clinical trial assessed the potential benefit of treatment with sorafenib after radical metastasectomy compared with […]

read more

Tivozanib in heavily pre-treated advanced kidney cancer patients

Further data from the TIVO-3 clinical trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC), which is unresponsive to treatment (refractory), has shown that at 32.5 months, 20 patients on tivozanib remain progression free, versus 2 patients on sorafenib. This is despite there being no positive effect on overall survival (median […]

read more

ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Rini from the Cleveland Clinic Taussig Cancer Institute presented the results from a phase 3 clinical trial (TIVO-3) to compare the efficacy and safety of tivozanib to sorafenib in patients […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer

According to the results of a recent meta-analysis of three phase III studies, adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) has no compelling benefit in the treatment of high-risk renal cell carcinoma (RCC). The meta-analysis was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting this week. […]

read more

Status of adjuvant therapy for the treatment of kidney cancer

Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]

read more

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in New York discussed the past, present and future of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) for the treatment of advanced/metastatic renal cell carcinoma […]

read more

Adjuvant therapy for renal cell carcinoma

The following article is a good review of the data from recent clinical trials of adjuvant targeted therapy for renal cell carcinoma (RCC). Adjuvant therapy is the treatment received after surgery to prevent the cancer from spreading and/or returning. The success of targeted therapies, such as vascular endothelial growth factor (VEGF) inhibitors (sunitinib and pazopanib) […]

read more

Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions

The following articles discuss the use of neoadjuvant therapy (drug treatment given before surgery) and adjuvant therapy (drug treatment given after surgery) for renal cell carcinoma, including a summary of current clinical trials and future directions. Read the neoadjuvant article in UroToday here Read the adjuvant article in UroToday here

read more
Showing 1 to 10 of 18 results
  TOP